Harold R Collard1, Shih-Yin Chen2, Wei-Shi Yeh2, Qian Li3, Yuan-Chi Lee3, Alan Wang3, Ganesh Raghu4. 1. 1 University of California San Francisco, School of Medicine, San Francisco, California. 2. 2 Biogen, Health Economics and Outcomes Research, Global Market Access, Cambridge, and. 3. 3 Evidera, Retrospective Observational Studies, Lexington, Massachusetts; and. 4. 4 University of Washington, Medical Center, Seattle, Washington.
Abstract
RATIONALE: Management of idiopathic pulmonary fibrosis (IPF) is resource-intensive. Because an increasing prevalence of IPF was found among the elderly in the United States, it is important to understand the economic burden associated with the disease in this population. OBJECTIVES: To compare health care resource utilization and costs between patients with IPF and matched control subjects without IPF in Medicare, the largest U.S. payer covering the elderly. METHODS: Administrative claims from a 5% random sample of Medicare beneficiaries (aged 65+) from years 2000 to 2011 were analyzed. Incident patients with IPF were identified on the basis of International Classification of Diseases, ninth revision, Clinical Modification diagnosis codes, with at least 1 year of enrollment before (preindex) and after (postindex) the first diagnosis (index date). Up to five beneficiaries without IPF were matched to each patient with IPF, based on age, sex, race, and region. Annual health care resource utilization and medical costs (excluding outpatient drug costs) during the preindex and postindex periods were compared between patients with IPF and matched control subjects. MEASUREMENTS AND MAIN RESULTS: A total of 7,855 patients with IPF were matched to 38,856 control subjects. Compared with matched control subjects during the preindex period, patients with IPF had an 82% higher risk of hospitalization (28.8 vs. 15.8%), and 72% higher total medical costs ($10,124 vs. $5,888). Compared with matched control subjects during the postindex period, patients with IPF had a 134% higher risk of hospitalization (48.7 vs. 20.8%), similar increased risk of emergency room visits (39.6 vs. 17.5%), and 134% higher total medical costs ($20,887 vs. $8,932). CONCLUSIONS: In the U.S. Medicare population, patients with IPF incurred substantial health care resource utilization. The annual IPF-attributable medical cost to the U.S. health care system, excluding medication costs, is estimated at close to $2 billion.
RATIONALE: Management of idiopathic pulmonary fibrosis (IPF) is resource-intensive. Because an increasing prevalence of IPF was found among the elderly in the United States, it is important to understand the economic burden associated with the disease in this population. OBJECTIVES: To compare health care resource utilization and costs between patients with IPF and matched control subjects without IPF in Medicare, the largest U.S. payer covering the elderly. METHODS: Administrative claims from a 5% random sample of Medicare beneficiaries (aged 65+) from years 2000 to 2011 were analyzed. Incident patients with IPF were identified on the basis of International Classification of Diseases, ninth revision, Clinical Modification diagnosis codes, with at least 1 year of enrollment before (preindex) and after (postindex) the first diagnosis (index date). Up to five beneficiaries without IPF were matched to each patient with IPF, based on age, sex, race, and region. Annual health care resource utilization and medical costs (excluding outpatient drug costs) during the preindex and postindex periods were compared between patients with IPF and matched control subjects. MEASUREMENTS AND MAIN RESULTS: A total of 7,855 patients with IPF were matched to 38,856 control subjects. Compared with matched control subjects during the preindex period, patients with IPF had an 82% higher risk of hospitalization (28.8 vs. 15.8%), and 72% higher total medical costs ($10,124 vs. $5,888). Compared with matched control subjects during the postindex period, patients with IPF had a 134% higher risk of hospitalization (48.7 vs. 20.8%), similar increased risk of emergency room visits (39.6 vs. 17.5%), and 134% higher total medical costs ($20,887 vs. $8,932). CONCLUSIONS: In the U.S. Medicare population, patients with IPF incurred substantial health care resource utilization. The annual IPF-attributable medical cost to the U.S. health care system, excluding medication costs, is estimated at close to $2 billion.
Entities:
Keywords:
cost of illness; Medicare; idiopathic pulmonary fibrosis
Authors: Jennifer L Larson-Casey; Jessy S Deshane; Alan J Ryan; Victor J Thannickal; A Brent Carter Journal: Immunity Date: 2016-02-23 Impact factor: 31.745
Authors: Brett Ley; Jeffrey Swigris; Bann-Mo Day; John L Stauffer; Karina Raimundo; Willis Chou; Harold R Collard Journal: Am J Respir Crit Care Med Date: 2017-09-15 Impact factor: 21.405
Authors: Andrew J Bryant; Vinayak Shenoy; Chunhua Fu; George Marek; Kyle J Lorentsen; Erica L Herzog; Mark L Brantly; Dorina Avram; Edward W Scott Journal: Am J Respir Cell Mol Biol Date: 2018-02 Impact factor: 6.914
Authors: Janelle Vu Pugashetti; Aleksander Kitich; Shehabaldin Alqalyoobi; Anne-Catherine Maynard-Paquette; David Pritchard; Julia Graham; Noelle Boctor; Andrea Kulinich; Elyse Lafond; Elena Foster; Cesar Mendez; Saad Choudhry; Jean Chalaoui; Julie Morisset; Michael Kadoch; Justin M Oldham Journal: Chest Date: 2020-03-14 Impact factor: 9.410
Authors: Eric S White; Zea Borok; Kevin K Brown; Oliver Eickelberg; Andreas Guenther; R Gisli Jenkins; Martin Kolb; Fernando J Martinez; Jesse Roman; Patricia Sime Journal: Am J Respir Crit Care Med Date: 2016-04-01 Impact factor: 21.405